2.44
2.95%
0.07
After Hours:
2.45
0.01
+0.41%
Editas Medicine Inc stock is traded at $2.44, with a volume of 2.26M.
It is up +2.95% in the last 24 hours and down -25.84% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$2.37
Open:
$2.39
24h Volume:
2.26M
Relative Volume:
1.12
Market Cap:
$201.42M
Revenue:
$78.12M
Net Income/Loss:
$-153.22M
P/E Ratio:
-0.8243
EPS:
-2.96
Net Cash Flow:
$-136.90M
1W Performance:
-8.27%
1M Performance:
-25.84%
6M Performance:
-59.47%
1Y Performance:
-76.74%
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
EDIT | 2.44 | 201.42M | 78.12M | -153.22M | -136.90M | -2.96 |
VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-29-23 | Upgrade | Stifel | Hold → Buy |
Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Dec-13-22 | Initiated | Citigroup | Neutral |
Dec-06-22 | Resumed | Credit Suisse | Neutral |
Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-29-22 | Initiated | BofA Securities | Neutral |
Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
Sep-24-21 | Initiated | Stifel | Hold |
Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-09-21 | Upgrade | Truist | Hold → Buy |
Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
Apr-16-21 | Initiated | Goldman | Sell |
Mar-22-21 | Initiated | Credit Suisse | Outperform |
Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-26-21 | Downgrade | Truist | Buy → Hold |
Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Nov-03-20 | Initiated | Robert W. Baird | Underperform |
Jun-18-20 | Resumed | SunTrust | Buy |
Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Oct-10-18 | Initiated | Guggenheim | Neutral |
Sep-21-18 | Initiated | Raymond James | Outperform |
May-15-18 | Reiterated | Chardan Capital Markets | Buy |
Feb-13-18 | Initiated | CLSA | Underperform |
Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
Jul-14-17 | Initiated | SunTrust | Hold |
Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
Jun-02-16 | Initiated | Jefferies | Hold |
Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
Feb-29-16 | Initiated | JP Morgan | Neutral |
Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
EDIT (Editas Medicine) Price-to-Operating-Cash-Flow : (As of Nov. 22, 2024) - GuruFocus.com
Editas Medicine FY2024 EPS Forecast Lifted by Zacks Research - MarketBeat
EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com
Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding - Simply Wall St
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - MSN
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat
Editas Medicine stock hits 52-week low at $2.7 amid market challenges - Investing.com India
Editas Medicine's SWOT analysis: gene editing stock faces pivotal phase By Investing.com - Investing.com Australia
Editas Medicine's SWOT analysis: gene editing stock faces pivotal phase - Investing.com
Cantor Fitzgerald Expects Lower Earnings for Editas Medicine - MarketBeat
FY2024 EPS Estimate for Editas Medicine Raised by Analyst - MarketBeat
Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail
TSX Real Estate Capped Index (TTRE) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail
TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Bristol-Myers Squibb Company (BMY-N) QuotePress Release - The Globe and Mail
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
FY2024 EPS Estimate for Editas Medicine Lifted by Analyst - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Editas Medicine upgraded at Evercore on CRISPR platform - Seeking Alpha
Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
Editas Medicine to Present at 3 Major Healthcare Investor Conferences | EDIT Stock | EDIT Stock News - StockTitan
Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week - Simply Wall St
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% - Yahoo Finance
Editas downgraded to market perform by Raymond James - MSN
Editas Medicine (FRA:8EM) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Chardan Capital Reiterates Buy Rating for Editas Medicine (NASDAQ:EDIT) - MarketBeat
Editas Medicine Buy rating and $12 target reaffirmed by Chardan - Investing.com UK
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT) - StreetInsider.com
Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - GuruFocus.com
Editas Medicine maintains Perform rating at Oppenheimer By Investing.com - Investing.com UK
Royal Bank of Canada Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $5.00 - MarketBeat
Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results, Hits Expectations - MarketBeat
Editas Medicine target cut to $5 by Barclays on strategic outlook - Investing.com Canada
Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Editas Medicine (EDIT) PT Lowered to $5 at Barclays - StreetInsider.com
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - MSN
Truist cuts Editas Medicine target to $8, keeps buy rating By Investing.com - Investing.com Canada
Editas Medicine Reports Q3 2024 Results and Developments - TipRanks
Editas: Q3 Earnings Snapshot - The Washington Post
Editas Medicine (EDIT) PT Lowered to $5 at RBC Capital - StreetInsider.com
Editas downgraded to market perform by Raymond James (NASDAQ:EDIT) - Seeking Alpha
Editas Medicine (NASDAQ:EDIT) Downgraded by Raymond James to "Market Perform" - MarketBeat
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities - StreetInsider.com
Editas Medicine earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Editas Medicine Announces Third Quarter 2024 Results and Business Updates - The Manila Times
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):